文献速递肿瘤 PET/CT核素与放射性配体治疗

177Lu标记1C1m-Fc抗TEM-1抗体在软组织肉瘤中的临床前诊疗研究

177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma.
PubMed 文献 · EJNMMI Res · 2020-08-17

本研究将新型抗TEM-1 scFv-Fc融合抗体1C1m-Fc与DOTA偶联并用177Lu标记,在软组织肉瘤小鼠模型中评估其体内分布和SPECT/CT成像。标记后放射化学纯度达95%,免疫反应性为86%±4%;TEM-1阳性肿瘤较对照肿瘤在72小时SPECT/CT信号高1.9倍,提示TEM-1是软组织肉瘤诊疗一体化有前景的靶点。

要点

  • 1C1m-Fc经DOTA偶联后177Lu标记成功,放射化学纯度达95%。
  • 标记后抗体免疫反应性为86%±4%。
  • TEM-1阳性肿瘤72小时SPECT/CT信号较对照肿瘤高1.9倍。

核心结论

  • TEM-1是软组织肉瘤诊疗一体化有前景的靶点,1C1m-Fc是合适的靶向候选分子。
  • DOTA/抗体比例影响[177Lu]Lu-1C1m-Fc的体内分布。

研究设计与样本

  • 临床前研究:将抗TEM-1 scFv-Fc融合抗体1C1m-Fc与p-SCN-Bn-DOTA偶联并用177Lu标记。
  • 在TEM-1阳性(SK-N-AS)和阴性(HT-1080)肿瘤小鼠中行生物分布与SPECT/CT成像。
  • 基于生物分布结果估算器官吸收剂量。

主要发现

  • DOTA偶联和177Lu标记成功,放射化学纯度最高达95%。
  • 标记后免疫反应性为86%±4%。
  • 生物分布显示TEM-1阳性肿瘤特异性摄取,以肝脏为非特异性关键健康器官,特异性与每抗体螯合物数量相关。
  • TEM-1阳性肿瘤较对照肿瘤在72小时SPECT/CT信号高1.9倍。

临床怎么用

  • 临床前结果支持进一步优化偶联比例以获得最佳肿瘤/器官放射性比值。
  • 后续需在小鼠异种移植模型中进行治疗研究,为未来临床转化做准备。

局限性

  • 本研究为临床前小鼠模型研究,尚未在患者中验证。
  • 需进一步确定最佳偶联方案并开展治疗实验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TEM-1 (tumor endothelial marker-1) is a single-pass transmembrane cell surface glycoprotein expressed at high levels by tumor vasculature and malignant cells. We aimed to perform a preclinical investigation of a novel anti-TEM-1 scFv-Fc fusion antibody, 1C1m-Fc, which was radiolabeled with 177Lu for use in soft tissue sarcomas models. METHODS: 1C1m-Fc was first conjugated to p-SCN-Bn-DOTA using different excess molar ratios and labeled with 177Lu. To determine radiolabeled antibody immunoreactivity, Lindmo assays were performed. The in vivo behavior of [177Lu]Lu-1C1m-Fc was characterized in mice bearing TEM-1 positive (SK-N-AS) and negative (HT-1080) tumors by biodistribution and single-photon emission SPECT/CT imaging studies. Estimated organ absorbed doses were obtained based on biodistribution results. RESULTS: The DOTA conjugation and the labeling with 177Lu were successful with a radiochemical purity of up to 95%. Immunoreactivity after radiolabeling was 86% ± 4%. Biodistribution showed a specific uptake in TEM-1 positive tumor versus liver as critical non-specific healthy organ, and this specificity is correlated to the number of chelates per antibody. A 1.9-fold higher signal at 72 h was observed in SPECT/CT imaging in TEM-1 positive tumors versus control tumors. CONCLUSION: TEM-1 is a promising target that could allow a theranostic approach to soft-tissue sarcoma, and 1C1m-Fc appears to be a suitable targeting candidate. In this study, we observed the influence of the ratio DOTA/antibody on the biodistribution. The next step will be to investigate the best conjugation to achieve an optimal tumor-to-organ radioactivity ratio and to perform therapy in murine xenograft models as a prelude to future translation in patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Delage JA, Faivre-Chauvet A, Fierle JK, et al. 177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma. EJNMMI Res. 2020. PMID: 32804276. doi:10.1186/s13550-020-00685-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。